7 New Drugs for Primary Care: Q2 2019

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

News

Slideshow

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about? Click through to find out.

At the close of the second quarter, Patient Care has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Below you will find details on the first generic version of Narcan®--naloxone hydrochloride nasal spray for opioid overdose; the first and only topical lotion that combines halobetasol propionate and tazarotene for the treatment of plaque psoriasis; plus 5 more.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Patient Care Editorial Staff

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Patient Care Editorial Staff

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.